![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 17, 14351-14354, April 26, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
§,
,
,
,
¶,
,
, and
From the
Institute for Protein Research, Osaka
University, 3-2 Yamadaoka and
Research Institute for Microbial
Diseases, Osaka University, 3-1 Yamadaoka, Suita,
Osaka 565-0871, Japan
Received for publication, February 12, 2002, and in revised form, March 3, 2002
| |
ABSTRACT |
|---|
|
|
|---|
The carboxyl-terminal Src kinase (Csk) is an
indispensable negative regulator for the Src family tyrosine kinases
(SFKs) that play pivotal roles in various cell signalings. To
understand the molecular basis of the Csk-mediated regulation of SFKs,
we elucidated the crystal structure of full-length Csk. The Csk crystal
consists of six molecules classified as active or inactive states
according to the coordinations of catalytic residues. Csk assembles the SH2 and SH3 domains differently from inactive SFKs, and their binding
pockets are oriented outward enabling the intermolecular interaction.
In active molecules, the SH2-kinase and SH2-SH3 linkers are tightly
stuck to the N-lobe of the kinase domain to stabilize the active
conformation, and there is a direct linkage between the SH2 and the
kinase domains. In inactive molecules, the SH2 domains are rotated
destroying the linkage to the kinase domain. Cross-correlation matrices
for the active molecules reveal that the SH2 domain and the N-lobe of
the kinase domain move as a unit. These observations suggest that Csk
can be regulated through coupling of the SH2 and kinase domains and
that Csk provides a novel built-in activation mechanism for cytoplasmic
tyrosine kinases.
The Src family tyrosine kinases
(SFKs),1 benign relatives of
the oncogenic v-src gene product, are non-receptor types of
protein tyrosine kinases (PTKs) that are associated with the plasma
membrane through their fatty acylated N termini (1). The SFKs serve as
molecular switches involved in the initiation of a variety of cellular
events in the multicellular animals, including cell growth and
division, cell attachment and movement, differentiation, survival, and
death (2). The SFKs are ordinarily present in an inactive state in
which the phosphorylated C-terminal regulatory tyrosine binds to its
own SH2 domain (3). In response to an external stimulus, an SFK becomes
activated through dephosphorylation of the C-terminal tyrosine or
through binding to another protein that displaces the intramolecular
interaction. The phosphorylation of the regulatory tyrosine of SFK is
strictly controlled by another PTK, the C-terminal Src kinase (Csk) (4,
5). The loss-of-function of Csk leads to constitutive activation of
SFKs, accompanied by severe defects in embryonic development (5). In
contrast, gain-of-function of Csk can readily down-regulate
SFK-mediated cell signaling (6). Therefore, to understand the function
and regulation of SFKs, it is essential to clarify the regulation
mechanism controlling the phosphorylation of the critical C-terminal tyrosine.
Csk is a cytoplasmic PTK consisting of an SH3, an SH2, and a kinase
domain (4). Because it lacks an N-terminal acylation signal, an
autophosphorylation site, and a C-terminal regulatory tyrosine, all of
which are conserved among SFKs, the regulatory mechanism of Csk appears
to be quite different from those of SFKs. The molecular basis of Csk
regulation has so far been studied using mutated molecules and isolated
domains (7, 8). However, lack of the entire structure of Csk has
hampered the evaluation of their physiological roles. Some evidence
suggests that the SH2 and/or SH3 domain of Csk is essential for SFK
regulation (7, 9) and that recruitment to the membrane is required for
Csk function (6, 10). In this context, we and others have recently identified a membrane phosphoprotein that can tightly bind to the SH2
domain of Csk (Cbp or PAG) (11, 12). Upon phosphorylation, Cbp/PAG can
recruit Csk to a membrane microdomain, so-called lipid Rafts, to
terminate SFK signaling. More recently, we found that the binding to
the phosphorylated Cbp/PAG could directly activate Csk (13). Thus it is
likely that Cbp/PAG plays an important role in Csk regulation. On the
other hand, other proteins that could functionally bind to the SH2
domain of Csk, such as Paxillin and FAK, have been identified
previously (7). These findings suggest that Csk is regulated through
its SH2 domain in vivo, although the molecular basis of this
regulation remains thoroughly unknown. To address this issue, we here
elucidated the entire structure of Csk by crystallographic analysis.
Expression and Purification of Csk--
The full-length (amino
acids 1-450) rat Csk was expressed using baculovirus vector in insect
cells and purified essentially by the same methods as described
previously (13), except that Crystal Structure Analysis--
The purified Csk was
concentrated to ~12 mg/ml, mixed with 50 mM Hepes-NaOH
(pH 7.4) containing 1.90-1.95 M ammonium sulfate, and
crystallized in a sitting drop by vapor diffusion at 288 K for 1-2
months. All data were collected at the cryogenic temperature (around
100 K) using 25% (v/v) ethylene glycol as a cryoprotectant. The
native1, native2, and Hg data were collected on the PX210 (Oxford) at
BL44XU, Quantum4 (adsc) at BL40B2, and on the marCCD (Mar research) at
BL41XU in SPring-8, respectively. The diffraction images were reduced
and scaled with Mosflm (ccp4 (14)) and Scala (ccp4) in native1 and
Denzo/Scalepack (15) in native2 and Hg data sets. The intensities were
converted to the structure factor amplitudes with TRUNCATE (ccp4).
Subsequent phasing calculations were performed using native2 and Hg
data. The six Hg positions were first located using SHELXS-97 (16),
followed by the minor site specification, heavy atom parameter
refinement, and the SIRAS phase calculation with SHARP (17). The
density modification with SOLOMON (ccp4) permitted us clear
interpretation of the electron density map. The atomic model was built
using O (18) and refined with the native1 data set using CNS
(19). Of the 2,298 non-glycine and non-proline residues, 83.0% fell
into the most favored regions, 16.1% into the additional allowed
regions, 0.9% into the generously allowed regions, and no residue into
the disallowed regions of Ramachandran plot as defined in PROCHECK.
Coordinates have been deposited with the Protein Data Bank under
accession codes 1K9A.
Overview of Csk Structure--
The full-length rat Csk was
produced using a baculovirus vector in insect cells and purified
through sequential column chromatography. Although Csk from the brain
tissue (<0.01 mg/ml) behaved as a monomer (50 kDa) on gel filtration
chromatography (20), the highly concentrated Csk from insect cells (>1
mg/ml) was eluted with an apparent molecular size around 100 kDa (data
not shown). Sedimentation equilibrium analysis also revealed that Csk
is present as a dimer at concentrations around 1 mg/ml (data not
shown). These findings demonstrate that Csk tends to dimerize at high protein concentrations in vitro. The crystal structure of
Csk was solved by the heavy atom single isomorphous replacement method. Crystallographic data and refinement statistics are shown in Table I. An interesting feature of Csk crystal
is that it consists of six molecules divided into three pairs of
putative dimers per asymmetric unit. This is probably because of
oligomerization of Csk dimers during crystallization processes. The
dimers are made with loose interactions through the backside of the
kinase domains and the SH3 domains. Two of the six molecules, in
distinct dimers, make further contact with each other and appear to
have some distortions in their structures as described later. In every
molecule, however, the three functional domains, SH2, SH3, and kinase,
are arranged in a similar manner with the SH2 and SH3 domains
diametrically opposite on the top of the N-lobe of the kinase domain
(Fig. 1, A and C).
Although the position of the SH3 domain resembles the position of the
SH3 domain of inactive forms of SFKs, the position of the SH2 domain is
entirely different (3). In addition, there is no direct contact between
the SH2 and SH3 domains of Csk.
Arrangements of the SH2 and SH3 Domains--
The SH3 domains fold
canonically with two anti-parallel sheets of five Active Conformation of the Kinase Domain--
The kinase domains
of the four Csk molecules whose SH2 domains face to the left
in Fig. 1B can be readily superimposed on the kinase domain
of an active SFK, Lck (22). The positions of residues crucial for
catalytic activity (Asp-314, Asn-319, and Asp-332) and the critical ion
bridge that orients the
The similarity in active sites despite the absence of phosphate in the
activation loop suggests that another mechanism maintains the active
conformation of Csk. Previously it has been reported that deletion of
sequences preceding the kinase domain significantly reduces Csk
activity (7, 8, 25, 26), and a role of the SH3-SH2 linker in Csk
activation has been suggested (8). In a structure of the isolated
kinase domain bound to staurosporine, the helix Inactive Conformation of the Kinase Domain--
In contrast with
the active molecules, the two Csk molecules with rotated SH2 domains
appear to be inactive. These molecules are substantially different from
the active molecules in the backbone carbon positions of the N-lobe of
the kinase domain (Fig. 1B). Importantly, the critical ion
pair (between Glu-236 and Lys-222) is absent (Fig. 2C)
although the conformation of the catalytic domain is apparently
different from that of the isolated kinase domain bound to
staurosporine (27). Furthermore, there is a major difference between
the active and inactive molecules in the SH2-kinase interface (Fig. 3);
the interactions between the Regulatory Feature of Csk--
To address the above issue, we
calculated cross-correlation matrices for the deviations of the
backbone carbon atoms of the molecules in the crystal. The
cross-correlation matrix was recently found to be useful to assess
interdomain interactions in molecular dynamics studies (30).
Fortunately, our crystal contained multiple copies of Csk molecules in
an asymmetric unit, and we used four crystallographically independent
copies instead of conformational snapshots in the molecular dynamics
study. The C-lobes of the kinase domains were first superimposed by the
program LSQKAB (14), and then we generated a set of averaged
positions of the
The structure of Csk presented here highlights the functional
interactions of the catalytic domain with the SH2 domain and its
linkers and suggests a novel activation mechanism that is distinct from
the phosphorylation-dependent regulation of SFKs. The
presence of an inactive conformation of Csk, which is probably produced
by the unusual flexibility of the hinge region of the SH2 domain, also
suggests that there may be a dynamic equilibrium between active and
inactive Csk. It is known that a strong ligand of the SH2 domain, the
phosphorylated Cbp/PAG, could elicit potentially full activity of Csk
(13). Therefore, it is probable that binding of Cbp/PAG ligand
to the SH2 domain could fix the active state to make the kinase
constitutively active. It is also possible that the conformation
change induced by the SH2 ligand could affect the region responsible
for the substrate recognition. To verify these hypotheses, the
structural details of Csk association with Cbp/PAG are now under investigation.
Among the many types of cytoplasmic protein tyrosine kinases, including
the Fes, Abl, Syk, Tec, and Csk families, the SFKs are unusual in that
they are negatively regulated by phosphorylation of the C-terminal
regulatory site. The SH2 domain of the SFK serves as an acceptor for
the phosphorylated regulatory tyrosine. All the aforementioned
cytoplasmic tyrosine kinases also possess an SH2 domain adjacent to the
catalytic domain but have no C-terminal phosphotyrosine. Although the
actual roles of SH2 domains in these enzymes remain to be studied at
the molecular level, the structures of Csk presented here could be
representative of cytoplasmic tyrosine kinases other than SFKs.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
-octyl-D-glucoside
was added (instead of Nonidet P-40) to the buffer during chromatography
processes and that the final gel filtration chromatography was
performed in a buffer consisting of 100 mM Tris-HCl (pH
8.5), 150 mM NaCl, 5 mM
-mercaptoethanol, 1 mM EDTA, 5% glycerol, and 0.02%
-octyl-D-glucoside. Size estimation was carried out on a
Superdex200 HR10/30 column equilibrated with phosphate-buffered saline.
Sedimentation equilibrium was performed by ultracentrifugation at
17,000 rpm for 22 h. Concentration distributions were measured
using the Rayleigh interference optics.
![]()
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
Summery of crystallographic data and refinement statistics

View larger version (38K):
[in a new window]
Fig. 1.
A, ribbon diagram of a
representative Csk structure (active molecule) in the crystal. Domain
structures are distinctively colored: SH2 in blue, SH3 in
purple, N-lobe in dark green,
C-lobe in light green, and the activation segment
in red. B, superimposed model of the six Csk
molecules in an asymmetric unit. Active molecules are shown in
green and inactive molecules are in blue.
C, schematic models of the structures of Csk
(left) and c-Src (right). Peptide binding pockets
of the SH2 and SH3 domains are shown by hollows. The rotated
SH2 domain of the inactive molecule is colored pink.
Phosphate on the tail tyrosine (Tyr-527) of c-Src is colored
red.
-strands
sandwiched into a compact structure. There are virtually no differences
from the structure of an isolated Csk-SH3 domain (21) except that the
N-terminal region is disordered in the isolated SH3 domain (Fig.
1A). The peptide-binding pocket of the SH3 domain is
oriented outward (Fig. 1C) enabling the intermolecular interaction, and the interactions between the SH3 and SH2-kinase linker
observed in inactive SFK structures are absent. The SH2 domains are
also canonical, consisting of a central
-sheet flanked by two
-helices as in c-Src (Fig. 1A), although an insertion is
present in the loop region of the c-Src SH2 domain. However, a
significant difference can be observed in the orientations of the SH2
domains when all six Csk molecules are superimposed (Fig. 1B). In four Csk molecules, the ligand binding surfaces face
to the left in Fig. 1B, whereas those of the
other two are rotated upward ~60° (Fig. 1B). This
disorientation may reflect an unusual flexibility of the SH3-SH2 linker
and SH2-kinase linker, which form a hinge about which the SH2 domain
pivots. These two linkers make extensive hydrophobic contacts with the
N-lobe of the kinase domain (Fig. 1A and Fig. 3). In the
SH2-kinase linker, there is an
-helix, which is designated as
BC,
that is absent from SFKs (Fig. 1A). All the hydrophobic
residues involved in engaging the SH2 and kinase domains are highly
conserved among Csks derived from various species, suggesting that
docking of the SH2 linkers into the kinase domain is important for regulation.
-phosphate of ATP (Glu-236 in
C and
Lys-222 in
3) are consistent with those of Lck (Fig.
2, A and B). All
these features suggest that the four molecules are most likely to be
enzymatically active. The active site similarity with Lck is rather
remarkable considering that Csk differs from SFKs in its activation
loop (Fig. 2, red). The activation loop of Csk (331-348) is
four residues shorter than and diverged from that of Lck, and,
critically, it lacks a phosphorylated tyrosine residue (Fig.
2E). In addition, Csk residues are either substantially
displaced as compared with their counterparts in Lck (338-342,
346-349) or disordered (343-345). In SFKs, autophosphorylation of the
activation loop tyrosine is regulatory and essential for full catalytic
activity and for transforming potential (23, 24). In Lck, this
phosphotyrosine (Tyr-394) is essential to coordinate Arg-363
and Arg-387 and thus stabilize the active structure. In Csk, however,
the side chain of Lys-337, which corresponds to Arg-387 in Lck, has no
apparent coordinations to a specific partner, yet the main chain lies
within 1.5 Å of Lck Arg-337 when the C-lobes are superimposed.

View larger version (43K):
[in a new window]
Fig. 2.
Arrangements of the catalytically important
residues in Lck (A), active Csk and a simulated annealing
omit map at 1.5
in the vicinity of the salt bridge between Lys-222
and Glu-236 (B), inactive Csk (C), and the
isolated kinase domain of Csk (27) (D) are shown. The salt
bridge between Lys-222 and Glu-236 is indicated by dotted
line in A and B. E,
sequence alignment of the activation loops of Csk, Lck, c-Src
(Src) and insulin receptor kinase (IRK).
Autophosphorylated tyrosines are colored red.
C is kinked and
flexible, destroying the critical salt bridge between Lys-222 and
Glu-236 (Fig. 2D) (27). In the case of Lck, however, an
isolated kinase domain retains full activity (28). As already
mentioned, in Csk there are tight interactions between the two linkers
and the N-lobe of the kinase domain. Notably, the helix
C, which
positions Glu-236, is oriented by extensive contacts with the linkers
(Fig. 3). This resembles the case of CDK2
that is partially activated through binding to cyclin A (29). The
binding of cyclin A to the helix
C (containing PSTAIRE motif) of
CDK2 induces a dramatic change in the orientation of the helix
C so
that the catalytic residues are appropriately coordinated for the
catalysis. Therefore, instead of the activating phosphotyrosine, Csk
may require the interaction between the kinase domain and the
linkers to stabilize the active conformation.

View larger version (33K):
[in a new window]
Fig. 3.
Stereo representations of the interaction
between the SH3-SH2 linker, SH2-kinase linker, and the kinase domain in
active Csk (A) and inactive Csk
(B). The interaction between the
D-
E loop
and
3-
C loop cannot been seen in the inactive Csk.
D-
E loop of the SH2 domain and
3-
C loop in the N-lobe of kinase domain are absent in the
inactive molecules. These indicate that rotation of the SH2 domain
could affect the conformation of the N-lobe of the kinase domain,
implicating the functional relationship between the SH2 domain and the
kinase domain.
carbon. The correlation between two atoms
can be defined using the deviations from their respective average
positions. It is obvious that the correlation value for two atoms in
the same domain shows an absolute value close to 1 as the domain moves
en bloc. If two residues move independently, the correlation will be
near 0. It is usually observed that the correlation between two atoms
in the "superimposed" region is flattened to 0. As shown in Fig.
4, for four active-state molecules,
clusters of positive correlations between two atoms lie in the regions
indicating correlations between the SH2 domain and
1-
2 and
3-
C regions of the kinase domain. This indicates that these
segments deviate en bloc in the crystal, representing a functional
coupling between the SH2 and the kinase domain.

View larger version (127K):
[in a new window]
Fig. 4.
Cross-correlation matrices for the four
active Csk molecules. The SH2 domain (82-172),
1-
2 and
3-
C loop (204-207), and
3-
C loop and
C (225-243) are
emphasized by the bold lines. The C-lobes of four
molecules were superimposed prior to the calculation. The correlation
coefficients cij, which are plotted according to the
scale indicated on the top, are defined as
cij =
(ri·rj)/((
|ri|2)1/2(
|rj|2)1/2),
where ri is the deviation of the backbone carbon
position from the average position of the "i"th
residue.
| |
ACKNOWLEDGEMENTS |
|---|
We thank J. A. Cooper for discussions and comments on the manuscript, T. Hirose and A. Nagata for production of recombinant Csk in Sf9 cells, N. Ito for aid in matrix presentation, K. Yutani and M. Sakai for sedimentation equilibrium analysis, E. Yamashita for valuable technical comments and suggestions, and beamline staffs at SPring-8 including M. Kawamoto and K. Miura for help in data collection.
| |
FOOTNOTES |
|---|
* This work was supported in part by grants-in-aid from the Ministry of Education, Science, Sports and Culture of Japan and by grants from The Nagase Science and Technology Foundation, The Mitsubishi Foundation, Japan Research Foundation for Clinical Pharmacology, and The Program for Promotion of Fundamental Studies in Health Sciences of the Organization for Pharmaceutical Safety and Research.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The atomic coordinates and the structure factors (code 1K9A) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).
§ Present address: National Institute of Livestock and Grassland Science 2, Ikenodai, Kukizaki, Inashiki, Ibaraki 305-0901, Japan.
¶ To whom correspondence may be addressed. E-mail: okadam@ biken.osaka-u.ac.jp or atsushi@protein.osaka-u.ac.jp.
Published, JBC Papers in Press, March 7, 2002, DOI 10.1074/jbc.C200086200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: SFK, Src family tyrosine kinase; PTK, protein tyrosine kinase.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Brown, M. T.,
and Cooper, J. A.
(1996)
Biochim. Biophys. Acta
1287,
121-149[Medline]
[Order article via Infotrieve] |
| 2. |
Thomas, S. M.,
and Brugge, J. S.
(1997)
Annu. Rev. Cell Dev. Biol.
13,
513-609[CrossRef][Medline]
[Order article via Infotrieve] |
| 3. |
Xu, W.,
Harrison, S. C.,
and Eck, M. J.
(1997)
Nature
385,
595-602[CrossRef][Medline]
[Order article via Infotrieve] |
| 4. |
Nada, S.,
Okada, M.,
MacAuley, A.,
Cooper, J. A.,
and Nakagawa, H.
(1991)
Nature
351,
69-72[CrossRef][Medline]
[Order article via Infotrieve] |
| 5. |
Nada, S.,
Yagi, T.,
Takeda, H.,
Tokunaga, T.,
Nakagawa, H.,
Ikawa, Y.,
Okada, M.,
and Aizawa, S.
(1993)
Cell
73,
1125-1135[CrossRef][Medline]
[Order article via Infotrieve] |
| 6. |
Chow, L. M.,
Fournel, M.,
Davidson, D.,
and Veillette, A.
(1993)
Nature
365,
156-160[CrossRef][Medline]
[Order article via Infotrieve] |
| 7. |
Sabe, H.,
Hata, A.,
Okada, M.,
Nakagawa, H.,
and Hanafusa, H.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
3984-3988 |
| 8. |
Shekhtman, A.,
Ghose, R.,
Wang, D.,
Cole, P. A.,
and Cowburn, D.
(2001)
J. Mol. Biol.
314,
129-138[CrossRef][Medline]
[Order article via Infotrieve] |
| 9. |
Cloutier, J. F.,
Chow, J. M.,
and Veillette, A.
(1995)
Mol. Cell. Biol.
15,
5937-5944[Abstract] |
| 10. |
Howell, B. W.,
and Cooper, J. A.
(1994)
Mol. Cell. Biol.
14,
5402-5411 |
| 11. |
Kawabuchi, M.,
Satomi, Y.,
Takao, T.,
Shimonishi, Y.,
Nada, S.,
Nagai, K.,
Tarakhovsky, A.,
and Okada, M.
(2000)
Nature
404,
999-1003[CrossRef][Medline]
[Order article via Infotrieve] |
| 12. |
Brdicka, T.,
Pavlistova, D.,
Leo, A.,
Bruyns, E.,
Korinek, V.,
Angelisova, P.,
Scherer, J.,
Shevchenko, A.,
Hilgert, I.,
Cerny, J.,
Drbal, K.,
Kuramitsu, Y.,
Kornacker, B.,
Horejsi, V.,
and Schraven, B.
(2000)
J. Exp. Med.
191,
1591-1604 |
| 13. |
Takeuchi, S.,
Takayama, Y.,
Ogawa, A.,
Tamura, K.,
and Okada, M.
(2000)
J. Biol. Chem.
275,
29183-29186 |
| 14. |
Collaborative Computing Project 4.
(1994)
Acta Crystallogr. Sect. D Biol. Crystallogr.
50,
760-763[CrossRef][Medline]
[Order article via Infotrieve] |
| 15. |
Otwinowski, Z.,
and Minor, W.
(1997)
Methods Enzymol.
276,
307-326 |
| 16. |
Sheldrick, G.
(1997)
Methods Enzymol.
276,
628-641 |
| 17. |
de La Fortelle, E.,
and Bricogne, G.
(1997)
Methods Enzymol.
276,
472-494 |
| 18. |
Jones, T. A.,
Zou, J. Y.,
Cowan, S. W.,
and Kjeldgaard, M.
(1991)
Acta Crystallogr. Sect. A
47,
110-119 |
| 19. |
Brünger, A. T.,
Adams, P. D.,
Clore, G. M.,
DeLano, W. L.,
Gros, P.,
Grosse-Kunstleve, R. W.,
Jiang, J. S.,
Kuszewski, J.,
Nilges, M.,
Pannu, N. S.,
Read, R. J.,
Rice, L. M.,
Simonson, T.,
and Warren, G. L.
(1998)
Acta Crystallogr. Sect. D Biol. Crystallogr.
54,
905-921[CrossRef][Medline]
[Order article via Infotrieve] |
| 20. |
Okada, M.,
and Nakagawa, H.
(1989)
J. Biol. Chem.
264,
20886-20893 |
| 21. |
Borchert, T. V.,
Mathieu, M.,
Zeelen, J. P.,
Courtneidge, S. A.,
and Wierenga, R. K.
(1994)
FEBS Lett.
341,
79-85[CrossRef][Medline]
[Order article via Infotrieve] |
| 22. |
Yamaguchi, H.,
and Hendrickson, W. A.
(1996)
Nature
384,
484-489[CrossRef][Medline]
[Order article via Infotrieve] |
| 23. |
Gonfloni, S.,
Weijland, A.,
Kretzschmar, J.,
and Superti-Furga, G.
(2000)
Nat. Struct. Biol.
7,
281-286[CrossRef][Medline]
[Order article via Infotrieve] |
| 24. |
Sun, G.,
Ramdas, L.,
Wang, W.,
Vinci, J.,
McMurray, J.,
and Budde, R. J.
(2002)
Arch Biochem. Biophys.
397,
11-17[CrossRef][Medline]
[Order article via Infotrieve] |
| 25. |
Sondhi, D.,
and Cole, P. A.
(1999)
Biochemistry
38,
11147-11155[CrossRef][Medline]
[Order article via Infotrieve] |
| 26. |
Sun, G.,
and Budde, R. J.
(1999)
Arch. Biochem. Biophys.
367,
167-172[CrossRef][Medline]
[Order article via Infotrieve] |
| 27. |
Lamers, M. B.,
Antson, A. A.,
Hubbard, R. E.,
Scott, R. K.,
and Williams, D. H.
(1999)
J. Mol. Biol.
285,
713-725[CrossRef][Medline]
[Order article via Infotrieve] |
| 28. |
Zhu, X.,
Kim, J. L.,
Newcomb, J. R.,
Rose, P. E.,
Stover, D. R.,
Toledo, L. M.,
Zao, H.,
and Morqenstern, K. A.
(1999)
Structure Fold Des.
7,
651-661[Medline]
[Order article via Infotrieve] |
| 29. |
Jeffrey, P. D.,
Russo, A. A.,
Polyak, K.,
Gibbs, E.,
Hurwitz, J.,
Massaque, J.,
and Pavletich, N. P.
(1995)
Nature
376,
313-320[CrossRef][Medline]
[Order article via Infotrieve] |
| 30. |
Young, M. A.,
Gonfloni, S.,
Superti-Furga, G.,
Roux, B.,
and Kuriyan, J.
(2001)
Cell
105,
115-126[CrossRef][Medline]
[Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
H. Fuss, W. Dubitzky, C. S. Downes, and M. J. Kurth Src Family Kinases and Receptors: Analysis of Three Activation Mechanisms by Dynamic Systems Modeling Biophys. J., March 15, 2008; 94(6): 1995 - 2006. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Lieser, J. Shaffer, and J. A. Adams Src Tail Phosphorylation Is Limited by Structural Changes in the Regulatory Tyrosine Kinase Csk J. Biol. Chem., December 8, 2006; 281(49): 38004 - 38012. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Meyer, X. Qian, H.-C. Guo, and N. Rahimi Leucine Motif-dependent Tyrosine Autophosphorylation of Type III Receptor Tyrosine Kinases J. Biol. Chem., March 31, 2006; 281(13): 8620 - 8627. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Yokoyama, J. Lougheed, and W. T. Miller Phosphorylation of WASP by the Cdc42-associated Kinase ACK1: DUAL HYDROXYAMINO ACID SPECIFICITY IN A TYROSINE KINASE J. Biol. Chem., December 23, 2005; 280(51): 42219 - 42226. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Ayrapetov, N. H. Nam, G. Ye, A. Kumar, K. Parang, and G. Sun Functional Diversity of Csk, Chk, and Src SH2 Domains due to a Single Residue Variation J. Biol. Chem., July 8, 2005; 280(27): 25780 - 25787. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Lieser, C. Shindler, B. E. Aubol, S. Lee, G. Sun, and J. A. Adams Phosphoryl Transfer Step in the C-terminal Src Kinase Controls Src Recognition J. Biol. Chem., March 4, 2005; 280(9): 7769 - 7776. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Lougheed, R.-H. Chen, P. Mak, and T. J. Stout Crystal Structures of the Phosphorylated and Unphosphorylated Kinase Domains of the Cdc42-associated Tyrosine Kinase ACK1 J. Biol. Chem., October 15, 2004; 279(42): 44039 - 44045. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lee, X. Lin, N. H. Nam, K. Parang, and G. Sun Determination of the substrate-docking site of protein tyrosine kinase C-terminal Src kinase PNAS, December 9, 2003; 100(25): 14707 - 14712. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nada, T. Shima, H. Yanai, H. Husi, S. G. N. Grant, M. Okada, and T. Akiyama Identification of PSD-93 as a Substrate for the Src Family Tyrosine Kinase Fyn J. Biol. Chem., November 28, 2003; 278(48): 47610 - 47621. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Lin, S. Lee, and G. Sun Functions of the Activation Loop in Csk Protein-tyrosine Kinase J. Biol. Chem., June 20, 2003; 278(26): 24072 - 24077. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Stamos, M. X. Sliwkowski, and C. Eigenbrot Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor J. Biol. Chem., November 22, 2002; 277(48): 46265 - 46272. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Wang, W. J. Esselman, and P. A. Cole Substrate Conformational Restriction and CD45-catalyzed Dephosphorylation of Tail Tyrosine-phosphorylated Src Protein J. Biol. Chem., October 18, 2002; 277(43): 40428 - 40433. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |